Ascendance of US President Trump to throne numbed the Indian Pharma industry (and also IT sector). For last 4-5 years US FDA's (US is one of the most lucrative markets for Indian Pharma) onsite scrutiny and warnings are making it difficult for this manufacturing sector to work. Stocks of big companies nosedived (for example: Wockhardt, Lupin, Auropharma, SunPharma etc.). However in recent months things have been changing for the better and some Pharma majors are showing signs of recovery. Divis is one such stock. Price created a bottom and took support therefrom. Five waves up are done and now consolidation is going on and well-defined resistance level is being hit clearing of which will give a breakout taking the price to new height.